Abstract
The receptor for urokinase plasminogen activator (uPAR) is required in hematopoietic stem/progenitor cells (HSC, HPC) mobilization in the mouse. Indeed, uPAR Ko mice are deficient both in retention and mobilization of HSC and HPC, because uPAR causes their retention in the BM through its interaction with the α4β1 integrin and at the same time its removal promotes their migration. Normally, the membrane signal is cleaved by plasmin which on one side releases the cells from their osteoblasts interaction and on the other produces a cleaved soluble uPAR product that stimulates mobilization. Available data suggest that a similar mechanism may take place in humans.
Keywords: Urokinase receptor, hematopoietic stem cells, mobilization, plasminogen activation, mutagenesis, chemotaxis, fibrinolysys, intravasation, migration, plasmin, phenotype, myeloid precursors, mouse keratinocytes, chemoresistance, hematopoietic progenitor cells
Current Pharmaceutical Design
Title: The Urokinase Receptor in Hematopoietic Stem Cells Mobilization
Volume: 17 Issue: 19
Author(s): Francesco Blasi
Affiliation:
Keywords: Urokinase receptor, hematopoietic stem cells, mobilization, plasminogen activation, mutagenesis, chemotaxis, fibrinolysys, intravasation, migration, plasmin, phenotype, myeloid precursors, mouse keratinocytes, chemoresistance, hematopoietic progenitor cells
Abstract: The receptor for urokinase plasminogen activator (uPAR) is required in hematopoietic stem/progenitor cells (HSC, HPC) mobilization in the mouse. Indeed, uPAR Ko mice are deficient both in retention and mobilization of HSC and HPC, because uPAR causes their retention in the BM through its interaction with the α4β1 integrin and at the same time its removal promotes their migration. Normally, the membrane signal is cleaved by plasmin which on one side releases the cells from their osteoblasts interaction and on the other produces a cleaved soluble uPAR product that stimulates mobilization. Available data suggest that a similar mechanism may take place in humans.
Export Options
About this article
Cite this article as:
Blasi Francesco, The Urokinase Receptor in Hematopoietic Stem Cells Mobilization, Current Pharmaceutical Design 2011; 17 (19) . https://dx.doi.org/10.2174/138161211796718206
DOI https://dx.doi.org/10.2174/138161211796718206 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry Lithium - Pharmacological and Toxicological Aspects: The Current State of the Art
Current Medicinal Chemistry Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Cyclooxygenase-2 Biology
Current Pharmaceutical Design SAR131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis through Bcl- 2/Bax/Cyto c Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells
Anti-Cancer Agents in Medicinal Chemistry A Tropical Lichen, Dirinaria consimilis Selectively Induces Apoptosis in MCF-7 Cells through the Regulation of p53 and Caspase-Cascade Pathway
Anti-Cancer Agents in Medicinal Chemistry The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy
Current Pharmaceutical Design Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Application of Functional Genomics to Bronchial Asthma
Current Pharmacogenomics Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma
Current Cancer Therapy Reviews MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis
Current Drug Targets Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors
Current Pharmaceutical Biotechnology Recent Design and Structure-Activity Relationship Studies on the Modifications of DHFR Inhibitors as Anticancer Agents
Current Medicinal Chemistry Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Regenerative Potential of Stem Cells Derived from Human Exfoliated Deciduous (SHED) Teeth during Engineering of Human Body Tissues
Current Stem Cell Research & Therapy